Radiopharmaceutical
Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.
The main group of these compounds are the radiotracers used to diagnose dysfunction in body tissues. While not all medical isotopes are radioactive, radiopharmaceuticals are the oldest and remain the most common of such drugs.
Drug nomenclature
As with other pharmaceutical drugs, there is standardization of the drug nomenclature for radiopharmaceuticals, although various standards coexist. The International Nonproprietary Names, United States Pharmacopeia names, and IUPAC names for these agents are usually similar other than trivial style differences. The details are explained at Radiopharmacology § Drug nomenclature for radiopharmaceuticals.Specific radiopharmaceuticals
A list of nuclear medicine radiopharmaceuticals follows. Some radioisotopes are used in ionic or inert form without attachment to a pharmaceutical; these are also included. There is a section for each radioisotope with a table of radiopharmaceuticals using that radioisotope. The sections are ordered by atomic number of the radioisotope. Sections for the same element are then ordered by atomic mass number.Hydrogen-3
3H or tritium is a beta emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| H3-water | Total body water | Oral or IV | In-vitro | Non-imaging |
Carbon-11
11C is a positron emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| C11-L-methyl-methionine | Brain tumour imaging Parathyroid imaging | IV | In-vivo | Imaging |
Carbon-14
is a beta emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| C14-Glycocholic acid | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
| C14-PABA | Pancreatic studies | Oral | In-vitro | Non-imaging |
| C14-Urea | Breath test to detect Helicobacter pylori | Oral | In-vitro | Non-imaging |
| C14-d-xylose | Breath test for small intestine bacterial overgrowth | Oral | In-vitro | Non-imaging |
Nitrogen-13
is a positron emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| N13-Ammonia | Myocardial blood flow imaging | IV | In-vivo | Imaging |
Oxygen-15
is a positron emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| O15-Water | Cerebral blood flow imaging Myocardial blood flow imaging | IV bolus | In-vivo | Imaging |
Fluorine-18
is a positron emitter with a half-life of 109 minutes. It is produced in medical cyclotrons, usually from oxygen-18, and then chemically attached to a pharmaceutical formulation.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| F18-FDG | Tumor imaging Myocardial imaging | IV | In-vivo | Imaging |
| F18-Sodium Fluoride | Bone imaging | IV | In-vivo | Imaging |
| F18-Fluorocholine | Prostate tumor imaging | IV | In-vivo | Imaging |
| F18-Desmethoxyfallypride | Dopamine receptor imaging | IV | In-vivo | Imaging |
Sodium-22
is a positron and gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Na22-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
Sodium-24
is a beta and gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Na24-Na+ | Electrolyte studies | Oral or IV | In-vitro | Non-imaging |
Phosphorus-32
is a beta emitter.| Name | Treatment of | Route of administration |
| P32-Phosphate | Polycythemia and related disorders | IV or Oral |
Calcium-47
47Ca is a beta and gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Ca-47-Ca2+ | Bone metabolism | IV | In-vitro | Non-imaging |
Chromium-51
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Cr51-heart scan/blood volume | Red cell volume [heart scan; sites of sequestration; gastrointestinal blood loss | IV | In-vitro | Non-imaging |
| Cr51-Cr3+ | Gastrointestinal protein loss | IV | In-vitro | Non-imaging |
| Cr51-EDTA | Glomerular filtration rate measurement | IV | In-vitro | Non-imaging |
Iron-59
is a beta and gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Fe59-Fe2+ or Fe3+ | Iron metabolism | IV | In-vitro | Non-imaging |
Cobalt-57
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Co57-Cyanocobalamin | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Cobalt-58
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Co58-Cyanocobalamin | Gastrointestinal absorption | Oral | In-vitro | Non-imaging |
Gallium-67
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Ga67-Ga3+ | Tumor imaging | IV | In-vivo | Imaging |
| Ga67-Ga3+ | Infection/inflammation imaging | IV | In-vivo | Imaging |
Gallium-68
is a positron emitter, with a 68-minute half-life, produced by elution from germanium-68 in a gallium-68 generator or by proton irradiation of zinc-68.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Ga68-Dotatoc or Dotatate | Neuroendocrine tumor imaging | IV | In-vivo | Imaging |
| Ga68-PSMA | Prostate cancer imaging | IV | In-vivo | Imaging |
Selenium-75
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Se75-Selenorcholesterol | Adrenal gland imaging | IV | In-vivo | Imaging |
| Se75-SeHCAT | Bile salt absorption | Oral | In-vivo | Imaging |
Krypton-81m
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging the radioactive substance |
| Kr81m-Gas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
| Kr-81m-Aqueous solution | Lung perfusion imaging | IV | In-vivo | Imaging |
Rubidium-82
is a positron and gamma emitter.| Name | Investigation of | Route of administration |
| Rb-82 chloride | Myocardial Imaging | IV |
Strontium-89
is a beta emitter.| Name | Treatment of | Route of administration |
| Sr89-Chloride | Bone metastases | IV |
Yttrium-90
is a beta emitter.| Name | Treatment of | Route of administration |
| Y90-Silicate | Arthritic conditions | Intra-articular |
| Y90-Silicate | Malignant disease | Intracavitary |
Technetium-99m
is a gamma emitter. It is obtained on-site at the imaging center as the soluble pertechnetate which is eluted from a technetium-99m generator, and then either used directly as this soluble salt, or else used to synthesize a number of technetium-99m-based radiopharmaceuticals.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Tc99m-pertechnetate | Thyroid uptake and thyroid imaging Stomach and salivary gland imaging Meckel's diverticulum imaging Brain imaging Micturating cystogram First pass blood flow imaging First pass peripheral vascular imaging | IV | In-vivo | Imaging |
| Tc99m-pertechnetate | Lacrimal imaging | Eye drops | In-vivo | Imaging |
| Tc99m-Human albumin | Cardiac blood pool imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin | Peripheral vascular imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging | IV | In-vivo | Imaging |
| Tc99m-Human albumin macroaggregates or microspheres | Lung perfusion imaging with venography | IV | In-vivo | Imaging |
| Tc99m-Phosphonates and phosphates | Bone imaging | IV | In-vivo | Imaging |
| Tc99m-Phosphonates and phosphates | Myocardial imaging | IV | In-vivo | Imaging |
| Tc99m-DTPA | Renal imaging First pass blood flow studies Brain imaging | IV | In-vivo | Imaging |
| Tc99m-DTPA | Lung ventilation imaging | Aerosol inhalation | In-vivo | Imaging |
| Tc99m-DMSA | Tumor imaging | IV | In-vivo | Imaging |
| Tc99m-DMSA | Renal imaging | IV | In-vivo | Imaging |
| Tc99m-Colloid | Bone marrow imaging GI Bleeding | IV | In-vivo | Imaging |
| Tc99m-Colloid | Lymph node imaging | Interstitial | In-vivo | Imaging |
| Tc99m-Colloid | Esophageal transit and reflux imaging Gastric emptying imaging | Oral | In-vivo | Imaging |
| Tc99m-Colloid | Lacrimal imaging | Eye drops | In-vivo | Imaging |
| Tc99m-HIDA | Functional biliary system imaging | IV | In-vivo | Imaging |
| Tc99m-Denatured red blood cells | Red cell volume Spleen imaging | IV | In-vitro | Non-imaging |
| Tc99m-Whole red blood cells | GI bleeding Cardiac blood pool imaging Peripheral vascular imaging | IV | In-vivo | Imaging |
| Tc99m-MAG3 | Renal imaging First pass blood flow imaging | IV | In-vivo | Imaging |
| Tc99m-Exametazime | Cerebral blood flow imaging | IV | In-vivo | Imaging |
| Tc99m-Exametazime labelled leucocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Sestamibi | Parathyroid imaging Non-specific tumor imaging Thyroid tumor imaging Breast imaging Myocardial imaging | IV | In-vivo | Imaging |
| Tc99m-Sulesomab | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Technegas | Lung ventilation imaging | Inhalation | In-vivo | Imaging |
| Tc99m-Human immunoglobulin | Infection/inflammation imaging | IV | In-vivo | Imaging |
| Tc99m-Tetrofosmin | Parathyroid imaging Myocardial imaging | IV | In-vivo | Imaging |
| Tc99m-ECD | Brain imaging----- | IV | In-vivo | Imaging |
Indium-111
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| In111-DTPA | Ventriculo-peritoneal shunt | intraperitoneal injection | In-vivo | Imaging the radioactive substance |
| In111-DTPA | Cisternography | Intra-cisternal | In-vivo | Imaging |
| In111-Leukocytes | Infection/inflammation imaging | IV | In-vivo | Imaging |
| In111-Platelets | Thrombus imaging | IV | In-vivo | Imaging |
| In111-Pentetreotide | Somatostatin receptor imaging | IV | In-vivo | Imaging |
| In111-Octreotide | Somatostatin receptor imaging | IV | In-vivo | Imaging |
Iodine-123
is a gamma emitter. It is used only diagnostically, as its radiation is penetrating and short-lived.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| I123-Iodide | Thyroid uptake | Oral or IV | In-vivo | Non-imaging |
| I123-Iodide | Thyroid imaging Thyroid metastases imaging | Oral or IV | In-vivo | Imaging |
| I123-o-Iodohippurate | Renal imaging | IV | In-vivo | Imaging |
| I123-MIBG | Neuroectodermal tumour imaging | IV | In-vivo | Imaging |
| I123-FP-CIT | SPECT imaging of Parkinson's Disease | IV | In-vivo | Imaging |
Iodine-125
is a gamma emitter with a long half-life of 59.4 days. Iodine-123 is preferred for imaging, so I-125 is used diagnostically only when the test requires a longer period to prepare the radiopharmaceutical and trace it, such as a fibrinogen scan to diagnose clotting. I-125's gamma radiation is of medium penetration, making it more useful as a therapeutic isotope for brachytherapy implant of radioisotope capsules for local treatment of cancers.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| I125-fibrinogen | Clot imaging | IV | In-vivo | Imaging |
Iodine-131
is a beta and gamma emitter. It is used both to destroy thyroid and thyroid cancer tissues, and also other neuroendocrine tissues when used in MIBG. It can also be seen by a gamma camera, and can serve as a diagnostic imaging tracer, when treatment is also being attempted at the same time. However iodine-123 is usually preferred when only imaging is desired.Xenon-133
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Xe133-gas | Lung ventilation studies | Inhalation | In-vivo | Imaging |
| Xe133 in isotonic sodium chloride solution | Cerebral blood flow | IV | In-vivo | Imaging |
Samarium-153
is a beta and gamma emitter.| Name | Treatment of | Route of administration |
| Sm153-EDTMP | Bone metastases | IV |
Erbium-169
is a beta emitter.| Name | Treatment of | Route of administration |
| Er169-Colloid | Arthritic conditions | Intra-articular |
Lutetium-177
is a beta emitter.| Name | Treatment of | Route of administration | In-vitro / in-vivo |
| 177Lu-DOTA-TATE | gastroenteropancreatic neuroendocrine tumors | IV | In-vivo |
Thallium-201
is a gamma emitter.| Name | Investigation | Route of administration | In-vitro / in-vivo | Imaging / non-imaging |
| Tl201-Tl+ | Non-specific tumor imaging Thyroid tumor imaging Myocardial imaging Parathyroid imaging | IV | In-vivo | Imaging |
Radium-223
is an alpha emitter.| Name | Treatment of | Route of administration |
| Ra223 cation | metastatic cancer in bone | IV |